Literature DB >> 3973821

Ibuprofen stereoisomer hepatic clearance and distribution in normal and fatty in situ perfused rat liver.

J W Cox, S R Cox, G VanGiessen, M J Ruwart.   

Abstract

Ibuprofen is a 2-arylpropionic acid anti-inflammatory agent that undergoes stereoselective chiral inversion (R to S configuration) as well as oxidative metabolism in humans and rats. The present study was undertaken to define more clearly the role of the liver in ibuprofen stereoisomer clearance in both normal and disease states. Liver perfusion experiments were conducted with normal and fatty rat liver; chronic fatty liver was induced by nutritional deficiency and was used as a model of hepatotoxin-induced fatty liver in humans. Total (R)-ibuprofen clearance (ClRtot), chiral inversion-related clearance (ClRinv), (S)-ibuprofen clearance (ClS) and hepatic distribution coefficients for each stereoisomer (KR and KS) were calculated with a model that corrected for perfusate reservoir sampling. In both normal and fatty liver, ClRinv accounted for 60% of ClRtot, but ClRtot was 30% lower in fatty liver than in normal liver (P less than .001). ClS was 40% of ClRtot in normal liver and was not significantly different from the noninversion clearance of (R)-ibuprofen. ClS was unchanged between normal and fatty liver and KS was greater than KR in normal liver (P = .01) but not in fatty liver. The results indicate that the fatty liver condition stereoselectively affects (R)-ibuprofen clearance and eliminates preferential (S)-isomer hepatic distribution. Based on model simulations, these effects are predicted to have minimal impact on total ibuprofen plasma levels or area-under-curve measurements following a dose of rac-ibuprofen unless ClRtot is reduced by more than 50%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973821

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Receptor-recycling model of clearance and distribution of insulin in the perfused mouse liver.

Authors:  H Sato; T Terasaki; H Mizuguchi; K Okumura; A Tsuji
Journal:  Diabetologia       Date:  1991-09       Impact factor: 10.122

4.  Stereoselective plasma protein binding of ibuprofen enantiomers.

Authors:  A M Evans; R L Nation; L N Sansom; F Bochner; A A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs.

Authors:  F Jamali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Jan-Mar       Impact factor: 2.441

6.  Stereoselective disposition of suspensions of conventional and wax-matrix sustained release ibuprofen microspheres in rats.

Authors:  C M Adeyeye; F F Chen
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

7.  Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations.

Authors:  G Li; G Treiber; K Maier; S Walker; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

8.  Pharmacokinetics of ibuprofen enantiomers in humans following oral administration of tablets with different absorption rates.

Authors:  F Jamali; N N Singh; F M Pasutto; A S Russell; R T Coutts
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

9.  Pharmacokinetic analysis of the enantiomeric inversion of chiral nonsteroidal antiinflammatory drugs.

Authors:  R Mehvar; F Jamali
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

10.  Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.

Authors:  H Cheng; J D Rogers; J L Demetriades; S D Holland; J R Seibold; E Depuy
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.